BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had eased Camzyos’ maintenance echo monitoring requirements to two from four per year and that the FDA accepted an application to similarly revisit U.S. requirements with a PDUFA target in April. The firm says this news has “negative commercial readthroughs” for Cytokinetics, which has long-maintained aficamten’s differentiated molecular profile would justify a relatively improved REMS and enable it to capture greater share of the hypertrophic cardiomyopathy market. BofA has a Neutral rating and $62 price target on Cytokinetics shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics share weakness on updated Camzyos REMS overdone, says Truist
- Netflix upgraded, Reddit downgraded: Wall Street’s top analyst calls
- Cytokinetics initiated with a Buy at Stifel
- Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586
- Cytokinetics CEO not looking to be bought, but would listen, STAT says